# CJC-1295 References — Full citation list with DOI and PubMed links

> Every citation used on this site, with author list, journal, year, DOI, and PubMed or ClinicalTrials.gov link. Compiled from the published CJC-1295 research record.

Compiled from the published CJC-1295 research record. Trace any claim on this site back to the source by reference number.

## How to read this list

Each reference is numbered to match the inline [N] markers used across the site. Where a peer-reviewed citation exists, the DOI is given; where the source is a regulatory document or a registry record, a permanent URL is given instead. Hover any inline citation marker elsewhere on the site to see the full citation; the same data is presented here in standard reference-list form for any reader who wants the full inventory in one place.

## References

[1] Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. https://pubmed.ncbi.nlm.nih.gov/15817669/
[2] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
[3] ConjuChem Biotechnologies. A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. ClinicalTrials.gov identifier NCT00267527. Status: Terminated (October 2006). https://clinicaltrials.gov/study/NCT00267527
[4] Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-4. https://pubmed.ncbi.nlm.nih.gov/16822960/
[5] Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7. https://pubmed.ncbi.nlm.nih.gov/17018654/
[6] Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-7. https://pubmed.ncbi.nlm.nih.gov/19386527/
[7] U.S. Food and Drug Administration. October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee — Briefing Materials. FDA-2024-N-4777. https://www.fda.gov/media/182088/download
[8] U.S. Food and Drug Administration. December 4, 2024 Pharmacy Compounding Advisory Committee Meeting — Follow-up Briefing. FDA-2024-N-4777. https://www.fda.gov/media/183819/download
[9] World Anti-Doping Agency. The 2025 Prohibited List — World Anti-Doping Code International Standard. Section S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. https://www.wada-ama.org/en/prohibited-list
[10] Thomas A, Walpurgis K, Tretzel L, Brinkkötter P, Fußhöller G, Görgens C, Geyer H, Thevis M. Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples. J Mass Spectrom. 2024. https://pubmed.ncbi.nlm.nih.gov/38197510/
[11] Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-50. https://pubmed.ncbi.nlm.nih.gov/21204297/
[12] Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-82. https://pubmed.ncbi.nlm.nih.gov/2107173/
[13] Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-9. https://pubmed.ncbi.nlm.nih.gov/25027139/
[14] Van Hout MC, Hearne E. Netnography of female use of the synthetic growth hormone CJC-1295: pulses and potions. Subst Use Misuse. 2016;51(1):73-84. https://pubmed.ncbi.nlm.nih.gov/26771670/
[15] Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal conditions. Sports Med. 2026. PMID 41966639. https://pubmed.ncbi.nlm.nih.gov/41966639/
[16] Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353. https://pubmed.ncbi.nlm.nih.gov/15110491/
[17] GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron. J Clin Endocrinol Metab. 2002. PMID 11932310. https://pubmed.ncbi.nlm.nih.gov/11932310/
[18] Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity. J Clin Endocrinol Metab. 2011. PMID 20943777. https://pubmed.ncbi.nlm.nih.gov/20943777/
[19] Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. https://pubmed.ncbi.nlm.nih.gov/39537825/
[20] Modified GRF (1-29) - chemical and pharmacological description. Encyclopedic reference. 2024. https://en.wikipedia.org/wiki/Modified_GRF_(1-29)

---

An independent reading of publicly available CJC-1295 research — not a clinic, not a vendor, not a treatment recommendation.